The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) hit a new 52-week high and has $16.69 target or 8.00% above today’s $15.45 share price. The 5 months bullish chart indicates low risk for the $765.29 million company. The 1-year high was reported on Mar, 1 by Barchart.com. If the $16.69 price target is reached, the company will be worth $61.22 million more. The stock increased 4.60% or $0.68 during the last trading session, reaching $15.45. About 948,946 shares traded or 313.30% up from the average. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has risen 21.19% since March 1, 2017 and is uptrending. It has outperformed by 4.49% the S&P500.
Among 14 analysts covering PPL Corporation (NYSE:PPL), 6 have Buy rating, 1 Sell and 7 Hold. Therefore 43% are positive. PPL Corporation had 42 analyst reports since August 5, 2015 according to SRatingsIntel. On Wednesday, July 19 the stock rating was upgraded by Jefferies to “Buy”. Wolfe Research upgraded PPL Corporation (NYSE:PPL) on Wednesday, September 14 to “Outperform” rating. The stock of PPL Corporation (NYSE:PPL) earned “Buy” rating by SunTrust on Tuesday, October 10. The firm has “Hold” rating by Guggenheim given on Tuesday, January 2. Goldman Sachs downgraded the shares of PPL in report on Monday, October 19 to “Neutral” rating. The stock of PPL Corporation (NYSE:PPL) has “Equal-Weight” rating given on Monday, June 27 by Barclays Capital. The rating was downgraded by Goldman Sachs on Tuesday, January 17 to “Sell”. The firm has “Hold” rating by KeyBanc Capital Markets given on Wednesday, October 18. Deutsche Bank upgraded PPL Corporation (NYSE:PPL) on Friday, October 30 to “Buy” rating. SunTrust maintained the shares of PPL in report on Friday, February 23 with “Buy” rating. See PPL Corporation (NYSE:PPL) latest ratings:
23/02/2018 Broker: SunTrust Rating: Buy New Target: $36.0 Maintain
23/02/2018 Broker: UBS Old Rating: Buy New Rating: Buy Old Target: $37 New Target: $36 Maintain
12/02/2018 Broker: SunTrust Rating: Buy New Target: $37.0 Maintain
02/02/2018 Broker: UBS Rating: Buy New Target: $40 Initiates Coverage On
01/02/2018 Broker: RBC Capital Markets Rating: Hold New Target: $33.0 Maintain
18/01/2018 Broker: Deutsche Bank Rating: Buy New Target: $36.0 Upgrade
08/01/2018 Broker: SunTrust Rating: Buy New Target: $39.0 Maintain
02/01/2018 Broker: Guggenheim Rating: Hold New Target: $32.0 Maintain
26/12/2017 Broker: SunTrust Rating: Buy New Target: $42.0 Maintain
19/12/2017 Broker: Macquarie Research Old Rating: Neutral New Rating: Underperform Downgrade
Analysts await Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to report earnings on March, 15. They expect $-0.66 EPS, down 1.54% or $0.01 from last year’s $-0.65 per share. After $-0.65 actual EPS reported by Karyopharm Therapeutics Inc. for the previous quarter, Wall Street now forecasts 1.54% negative EPS growth.
Among 13 analysts covering Karyopharm Therapeutics Inc. (NASDAQ:KPTI), 12 have Buy rating, 1 Sell and 0 Hold. Therefore 92% are positive. Karyopharm Therapeutics Inc. has $42 highest and $10 lowest target. $24.36’s average target is 57.67% above currents $15.45 stock price. Karyopharm Therapeutics Inc. had 28 analyst reports since August 11, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, January 11 by H.C. Wainwright. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has “Overweight” rating given on Monday, March 14 by JP Morgan. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has “Hold” rating given on Wednesday, January 6 by Jefferies. The rating was maintained by H.C. Wainwright on Thursday, September 8 with “Buy”. The stock has “Buy” rating by H.C. Wainwright on Thursday, August 18. MLV maintained Karyopharm Therapeutics Inc. (NASDAQ:KPTI) rating on Wednesday, August 12. MLV has “Buy” rating and $42 target. The rating was initiated by Robert W. Baird on Tuesday, June 28 with “Outperform”. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has “Buy” rating given on Thursday, November 2 by RBC Capital Markets. Canaccord Genuity maintained the stock with “Buy” rating in Tuesday, August 8 report. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) earned “Hold” rating by Jefferies on Tuesday, March 15.
Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. The company has market cap of $765.29 million. The Company’s lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma. It currently has negative earnings. The firm is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-HodgkinÂ’s lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases.
Investors sentiment increased to 2.5 in 2017 Q3. Its up 0.94, from 1.56 in 2017Q2. It improved, as 5 investors sold Karyopharm Therapeutics Inc. shares while 11 reduced holdings. 7 funds opened positions while 33 raised stakes. 27.91 million shares or 3.47% more from 26.98 million shares in 2017Q2 were reported. Bnp Paribas Arbitrage Sa reported 0% of its portfolio in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Northern Tru holds 416,232 shares or 0% of its portfolio. Panagora Asset Mgmt accumulated 78,307 shares or 0% of the stock. Tower Research Capital Llc (Trc) holds 0.01% or 7,787 shares in its portfolio. D E Shaw & Com reported 60,549 shares stake. 1.77 million are held by Vanguard Gp. Tcw Grp Inc has 0% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Opus Point Prns Management Ltd Liability Com reported 100,000 shares. Moreover, Deutsche Bancorporation Ag has 0% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Art Advisors Limited Liability Com owns 26,552 shares. Millennium Management Ltd holds 0.01% or 370,916 shares in its portfolio. Thomas J Herzfeld Advsr Inc has 0.02% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for 4,868 shares. Alliancebernstein Lp accumulated 43,430 shares or 0% of the stock. Metropolitan Life Insur owns 21,911 shares for 0% of their portfolio. Nationwide Fund Advsr has invested 0% of its portfolio in Karyopharm Therapeutics Inc. (NASDAQ:KPTI).
Since September 11, 2017, it had 0 insider buys, and 19 sales for $1.58 million activity. Shacham Sharon sold $100,882 worth of stock. Primiano Christopher Brett sold $22,000 worth of stock or 2,000 shares. Kauffman Michael sold 10,000 shares worth $100,882. 118 shares were sold by Mirza Mansoor Raza, worth $1,298.
PPL Corporation, a utility company, delivers electricity and natural gas in the United States and the United Kingdom. The company has market cap of $19.58 billion. The firm operates in three divisions: U.K. It has a 17.2 P/E ratio. Regulated, Kentucky Regulated, and Pennsylvania Regulated.
The stock decreased 1.54% or $0.44 during the last trading session, reaching $28.21. About 6.33 million shares traded. PPL Corporation (NYSE:PPL) has risen 2.43% since March 1, 2017 and is uptrending. It has underperformed by 14.27% the S&P500.
The post Karyopharm Therapeutics Inc. (KPTI) Reaches $15.45 52-Week High; PPL (PPL) Had 6 Bullish Analysts appeared first on Stock Market News | HillCountryTimes | Get it Today.
from
https://www.hillcountrytimes.com/2018/03/01/karyopharm-therapeutics-inc-kpti-reaches-15-45-52-week-high-ppl-ppl-had-6-bullish-analysts/
No comments:
Post a Comment